Anti-TNF-α antibodies suppress the development of experimental autoimmune myasthenia gravis

Journal of Autoimmunity

Volumn 19, Issue 4, 2002, Pages 169-174

  Duan, Rui Sheng ^a,b   Wang, Hua Bing ^a   Yang, Jian She ^a   Scallon, Bernie ^c   Link, Hans ^a   Xiao, Bao Guo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c CENTOCOR INC   (United States)

Author keywords

Anti AChR antibodies; Anti TNF antibodies; Cytokine; Experimental autoimmune myasthenia gravis

Indexed keywords

CHOLINERGIC RECEPTOR; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; IMMUNIZATION; INCIDENCE; LYMPHOCYTE PROLIFERATION; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

EID: 0037005409     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2002.0618     Document Type: Article

References (31)

1. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330:1994;1797-1810.
2. Li H., Shi F.D., Bai X.F., Huang Y., Diab A., He B., Link H. Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis. J. Neurol. Sci. 161:1998;40-46.
3. Wang H.B., Li H., Shi F.D., Chambers B.J., Link H., Ljunggren H.G. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int. Immunol. 12:2000;1381-1388.
4. Zhang G.X., Yu L.Y., Shi F.D., Xiao B.G., Bjork J., Hedlund G., Link H. Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis. J. Neuroimmunol. 73:1997;175-182.
5. van Deventer S.J. Anti-TNF antibody treatment of Crohn's disease. Ann. Rheum. Dis. 58:1999;114-120.
6. Feldmann M., Bondeson J., Brennan F.M., Foxwell B.M., Maini R.N. The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards? Ann. Rheum. Dis. 58:1999;27-31.
7. Harriman G., Harper L.K., Schaible T.F. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann. Rheum. Dis. 58:1999;61-64.
8. Wildbaum G., Kain N. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis. Gene Ther. 6:1999;1128-1138.
9. Korner H., Lemckert F.A., Chaudhri G., Etteldorf S., Sedgwick J.D. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur. J. Immunol. 27:1997;1973-1981.
10. Lindstrom J., Einarson B., Tzartos S. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 74:1981;432-460.
11. Wang H.B., Shi F.D., Li H., Chambers B.J., Link H., Ljunggren H.G. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J. Immunol. 166:2001;6430-6436.
12. Im S.H., Barchan D., Maiti P.K., Raveh L., Souroujon M.C., Fuchs S. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. 15:2001;2140-2148.
13. Macdonald R.A., Hosking C.S., Jones C.L. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods. 106:1988;191-194.
14. Saoudi A., Bernard I., Hoedemaekers A., Cautain B., Martinez K., Druet P., De Baets M., Guery J.C. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats. J. Immunol. 162:1999;7189-7197.
15. Wu B., Deng C., Goluszko E., Christadoss P. Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J. Immunol. 159:1997;3016-3023.
16. Shi F.D., Bai X.F., Li H.L., Huang Y.M., Van der Meide P.H., Link H. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals. Clin. Exp. Immunol. 111:1998;506-512.
17. Yang B., McIntosh K.R., Drachman D.B. How subtle differences in MHC class II affect the severity of experimental myasthenia gravis. Clin. Immunol. Immunopathol. 86:1998;45-58.
18. Sidman C.L., Marshall J.D., Shultz L.D., Gray P.W., Johnson H.M. Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature. 309:1984;801-804.
19. Snapper C.M., Mond J.J. Towards a comprehensive view of immunoglobulin class switching. Immunol. Today. 14:0000;15-17.
20. Rizzo L.V., DeKruyff R.H., Umetsu D.T. Generation of B cell memory and affinity maturation. Induction with Th1 and Th2 T cell clones. J. Immunol. 148:1992;3733-3739.
21. Jelinek D.F., Lipsky P.E. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. J. Immunol. 139:1987;2970-2976.
22. Graus Y.M., van Breda Vriesman P.J., de Baets M.H. Characterization of anti-acetylcholine receptor (AChR) antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis (EAMG). Clin. Exp. Immunol. 92:1993;506-513.
23. Krolick K.A., Zoda T.E., Thompson P.A. Examination of characteristics that may distinguish disease-causing from benign AChR-reactive antibodies in experimental autoimmune myasthenia gravis. Adv. Neuroimmunol. 4:1994;475-493.
24. Howard M., O'Garra A. Biological properties of interleukin 10. Immunol. Today. 13:1992;198-200.
25. Hagenbaugh A., Sharma S., Dubinett S.M., Wei S.H.Y., Aranda R., Cheroutre H., Fowell D.J., Binder S., Tsao B., Locksley R.M., Moore K.W., Kronenberg M. Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med. 185:1997;2101-1210.
26. Matusevicius D., Navikas V., Palasik W., Pirskanen R., Fredrikson S., Link H. Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J. Neuroimmunol. 71:1996;191-198.
27. Poussin M.A., Goluszko E., Hughes T.K., Duchicella S.I., Christadoss P. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. J. Neuroimmunol. 111:2000;152-160.
28. Zhang G.X., Xiao B.G., Yu L., van der Meide P.H., Link H. Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. J. Neuroimmunol. 113:2001;10-18.
29. Huang Y.M., Kivisakk P., Ozenci V., Pirskanen R., Link H. Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG). Clin. Exp. Immunol. 118:1999;304-308.
30. Zhang G.X., Navikas V., Link H. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve. 20:1997;543-551.
31. Weissert R., Melms A., Link H. Altered tumor growth factor beta mRNA expression is associated with thymectomy-related clinical remission in myasthenia gravis. J. Neurol. Sci. 151:1997;49-55.